Yahoo Finance • 7 days ago

Onconetix announces financing through private placement, debt settlement

Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Preferred Stock, $0.00001 par value, and warrants to purchase up to an aggregate of 4,362,827 shar... Full story

Yahoo Finance • 8 days ago

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions... Full story

Yahoo Finance • 8 days ago

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a l... Full story

Yahoo Finance • 12 days ago

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for... Full story

Yahoo Finance • 3 months ago

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in th... Full story

Yahoo Finance • 3 months ago

Onconetix to buy privately held Ocuvex Therapeutics

[Two puzzle pieces connecting, one white and one grey, on a contrasting background.] mohd izzuan/iStock via Getty Images * Onconetix (NASDAQ:ONCO [https://seekingalpha.com/symbol/ONCO]) announced on Wednesday that it has agreed to purch... Full story

Yahoo Finance • 3 months ago

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercializa... Full story

Yahoo Finance • 4 months ago

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative soluti... Full story

Yahoo Finance • 4 months ago

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative soluti... Full story

Yahoo Finance • 4 months ago

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company’s... Full story

Yahoo Finance • 6 months ago

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercializ... Full story

Yahoo Finance • 7 months ago

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercializ... Full story